If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImperial Innovations Group Regulatory News (IVO)

  • There is currently no data for IVO

Directorate Change

23 Jul 2015 13:35

RNS Number : 9253T
Imperial Innovations Group plc
23 July 2015
 



23 July 2015

 

Imperial Innovations Group plc

 

Directorate Change

 

Imperial Innovations Group plc (AIM: IVO, 'the Group', 'Innovations') announces that its non-executive director Mark Rowan will resign from the Board on 31 July 2015.

 

Mark was appointed to the Board in April 2006, having been a director of the Group's subsidiary Imperial Innovations Ltd since January 2005. He joined Innovations after a career working at J.P. Morgan and American International Group and has also provided advice on strategic and structural issues to a broad spectrum of companies, including early-stage technology investments.

 

Mark served as the Chairman of the Group's Audit and Risk Committee since the Group's IPO in 2006. He also served on the Remuneration Committee and Nomination Committee.

 

Linda Wilding takes over as chair of the Audit and Risk Committee on 1 August 2015.

 

Martin Knight, Chairman of Imperial Innovations, said:

 

"On behalf of the Board I would like to thank Mark for more than ten years of service to the Group, during which time we have benefited from his extensive experience, wise counsel and financial expertise.

 

"He has played an important role in Innovations' evolution, from its IPO in 2006, to its current position as one of the UK's leading technology commercialisation companies.

 

"His legacy includes our sound financial controls and funding strategy, recent highlights of which include the execution of last year's £150m placing and obtaining £80m in loan facilities from the European Investment Bank (EIB).

 

"Mark has made a significant contribution to the success of the Group and we would all like to thank him for his service and offer him our best wishes for the future."

 

For further information contact:

 

Imperial Innovations Group plc

020 3053 8834

Martin Knight, Chairman

Jon Davies, Director of Communications

 

Instinctif Partners

020 7457 2020

Adrian Duffield/Melanie Toyne-Sewell

 

J.P. Morgan Cazenove (Nominated Adviser)

020 7742 4000

Michael Wentworth-Stanley/Alec Pratt

 

Cenkos Securities

020 7397 8900

Christopher Golden

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAPGUCWMUPAGPW
Date   Source Headline
12th Dec 20123:02 pmRNSResult of AGM
16th Nov 20127:00 amRNSVeryan CE Mark approval for BioMimics 3D Stent
5th Nov 20127:00 amRNSPortfolio companies receive government funding
19th Oct 201210:00 amRNSGrant of share options
5th Oct 20127:00 amRNSFull year results
4th Oct 20127:00 amRNSCircassia initiates phase III trial
26th Sep 20127:00 amRNSPsiOxus commences clinical trial
20th Sep 201212:39 pmRNSNotice of Results
13th Sep 20123:25 pmRNSCircassia appoints Dr Brett Haumann as CMO
12th Sep 201211:35 amRNSAward Win
6th Sep 20127:00 amRNSInvestment in Cambridge technology company
1st Aug 20123:58 pmRNSDirector Dealings
23rd Jul 20127:00 amRNSInvestment in portfolio company
11th Jul 20122:50 pmRNSVeryan Medical appoints new COO and NEDs
9th Jul 20127:00 amRNS£22m funding round for PsiOxus Therapeutics
5th Jul 20125:20 pmRNSGrant of share options
27th Jun 20128:12 amRNSAbingdon Health acquires controlling stake
18th Jun 20127:00 amRNSInvestment in Oxford healthcare company
12th Jun 20127:00 amRNSInvestment in Cambridge technology company
31st May 20129:36 amRNSDirector/PDMR Shareholding
29th May 201210:05 amRNSPolytherics expands relationship with Pro Bono Bio
24th May 20127:00 amRNSDirector Dealings
1st May 20123:04 pmRNSDirector Dealings
23rd Apr 20127:00 amRNSHalf year results
26th Mar 20123:51 pmRNSNotice of Results
26th Mar 20127:00 amRNSInvestment in portfolio company
21st Mar 20127:00 amRNSDirectorate Change
8th Mar 20127:00 amRNSCircassia Phase II Clinical Trial Success
13th Feb 20127:00 amRNSInvestment in portfolio company
14th Dec 20115:27 pmRNSResult of AGM
6th Dec 20117:00 amRNSInvestment in new start-up
5th Oct 20117:00 amRNSFinal Results
27th Sep 20118:56 amRNSNotice of Results
7th Sep 20117:00 amRNSFurther investment in portfolio company
25th Aug 20117:00 amRNSInvestment in Cambridge company
22nd Aug 20117:00 amRNSInvestment in new company
3rd Aug 20117:00 amRNSInvestment in portfolio company
20th Jul 20117:00 amRNSInvestment in Stanmore
22nd Jun 20119:35 amRNSPortfolio company joint venture
19th Apr 20117:00 amRNSCircassia raises £60m
19th Apr 20117:00 amRNSHalf Yearly Report
30th Mar 201112:41 pmRNSNotice of Results
7th Feb 20116:00 pmRNSNotification of major interest in shares
3rd Feb 20118:16 amRNSDirectors' Dealings
27th Jan 20112:56 pmRNSNotification of major interest in shares
27th Jan 20112:51 pmRNSNotification of major interest in shares
26th Jan 20116:01 pmRNSNotification of major interest in shares
25th Jan 20116:03 pmRNSDirectors' Dealings
25th Jan 20115:40 pmRNSResults of Rump placing
24th Jan 20114:11 pmRNSVoting rights & share capital

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.